{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:24Z","timestamp":1792979904080,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06061-2","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:13:55Z","timestamp":1759238035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug-related problems and challenges encountered by pharmacists in nirmatrelvir\/ritonavir counselling during the covid-19 pandemic: a multi-center study"],"prefix":"10.1038","volume":"15","author":[{"given":"Shamala","family":"Balan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavidha","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanitha Hong Wee","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanis Hazwanie","family":"Ghazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chew Li","family":"Suan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Chia","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong Wei","family":"En","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leana Fatimah","family":"Makhdzir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurul Syafiqah","family":"Samsuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Mazni Mohamad","family":"Tamyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Nazlim","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Amirah Mohd Noor","family":"Azami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaili","family":"Samad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiren Kaur Chut","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurfareeza Nazir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Hajar","family":"Chamati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurdiana","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuay Hue","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farraha","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lau Wai","family":"Hoong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azlen Awatif Abu","family":"Bakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"6061_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/jac\/dkad376","volume":"79","author":"M Cruciani","year":"2024","unstructured":"Cruciani, M., Pati, I., Masiello, F., Pupella, S. & De Angelis, V. Nirmatrelvir\/ritonavir for COVID-19: an overview of systematic reviews. J. Antimicrob. Chemother. 79, 477\u2013497 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"6061_CR2","doi-asserted-by":"publisher","first-page":"7485","DOI":"10.1038\/s41598-024-57633-7","volume":"14","author":"DE Malden","year":"2024","unstructured":"Malden, D. E. et al. Predictors of nirmatrelvir\u2013ritonavir receipt among COVID-19 patients in a large US health system. Sci. Rep. 14, 7485 (2024).","journal-title":"Sci. Rep."},{"key":"6061_CR3","doi-asserted-by":"crossref","unstructured":"Hashemian, S. M. R. et al. Paxlovid (Nirmatrelvir\/Ritonavir): A new approach to Covid-19 therapy? Biomed. Pharmacother. 114367 (2023).","DOI":"10.1016\/j.biopha.2023.114367"},{"key":"6061_CR4","doi-asserted-by":"crossref","unstructured":"Komorowski, A. S. et al. Evidence-based recommendations on the use of nirmatrelvir\/ritonavir (Paxlovid) for adults in Ontario. Ontario COVID-19 Science Advisory Table: Toronto, ON, Canada 3, 57 (2022).","DOI":"10.47326\/ocsat.2022.03.57.1.0"},{"key":"6061_CR5","doi-asserted-by":"crossref","unstructured":"Dahri, K. et al. Opportunities and challenges associated with the launch of nirmatrelvir\/ritonavir (Paxlovid) in British Columbia during the COVID-19 pandemic: A qualitative study to explore community pharmacists\u2019 perspectives. Can Pharm. J. : CPJ 17151635241288576 (2024).","DOI":"10.1177\/17151635241288577"},{"key":"6061_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40545-022-00469-1","volume":"15","author":"CT Chang","year":"2022","unstructured":"Chang, C. T., Ong, S. Y., Lim, X. J., Chew, L. S. & Rajan, P. Managing nirmatrelvir\/ritonavir during COVID-19: pharmacists\u2019 experiences from the Perak state of Malaysia. J. Pharm. Policy Pract. 15, 70 (2022).","journal-title":"J. Pharm. Policy Pract."},{"key":"6061_CR7","doi-asserted-by":"publisher","first-page":"993158","DOI":"10.3389\/fphar.2022.993158","volume":"13","author":"J Barcel\u00f3-Vidal","year":"2022","unstructured":"Barcel\u00f3-Vidal, J. et al. Drug-related problems in patients admitted for SARS-CoV-2 infection during the COVID-19 pandemic. Front. Pharmacol. 13, 993158 (2022).","journal-title":"Front. Pharmacol."},{"key":"6061_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11096-024-01852-5","volume":"47","author":"A Stoiber","year":"2025","unstructured":"Stoiber, A., Gray, G., Sailer, G., Huf, W. & Tonna, A. Frequency, type and severity of drug-related problems and pharmacist interventions in Paxlovid\u00ae prescribing: a descriptive analysis. Int. J. Clin. Pharm. 47, 471\u2013476 (2025).","journal-title":"Int. J. Clin. Pharm."},{"key":"6061_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.14235\/bas.galenos.2022.63935","volume":"10","author":"MY Bektay","year":"2022","unstructured":"Bektay, M. Y., Sancar, M., Okyaltirik, F. K., Durdu, B. & \u0130zzettin, F. V. Identification of drug-related problems and investigation of related factors in patients with COVID-19: an observational study. Bezmialem Sci. 10, 777\u2013785 (2022).","journal-title":"Bezmialem Sci."},{"key":"6061_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/pharmacy11030087","volume":"11","author":"D Kieck","year":"2023","unstructured":"Kieck, D., Mahalick, L. & Vo, T. T. Medication-related problems identified and addressed by pharmacists dispensing COVID-19 antivirals at a community pharmacy. Pharmacy 11, 87 (2023).","journal-title":"Pharmacy"},{"key":"6061_CR11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/08971900211065536","volume":"36","author":"O Al-Quteimat","year":"2023","unstructured":"Al-Quteimat, O., Siddiqui, M., Hussein, L., Al Emleh, H. & Shamieh, I. E. L. D. Analysis of pharmacist interventions in adult COVID-19 patients admitted to a tertiary care hospital. J. Pharm. Pract. 36, 572\u2013578 (2023).","journal-title":"J. Pharm. Pract."},{"key":"6061_CR12","doi-asserted-by":"publisher","first-page":"24750","DOI":"10.1038\/s41598-024-75192-9","volume":"14","author":"Z Zaharuddin","year":"2024","unstructured":"Zaharuddin, Z., Md Hussin, N. S. & Karuppannan, M. Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients. Sci. Rep. 14, 24750 (2024).","journal-title":"Sci. Rep."},{"key":"6061_CR13","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.3390\/jcm12144739","volume":"12","author":"JA Koeck","year":"2023","unstructured":"Koeck, J. A., Dohmen, S. M., Marx, G. & Eisert, A. Comparison of drug-related problems in COVID-19 and non-COVID-19 patients provided by a German telepharmacy service for rural intensive care units. J. Clin. Med. 12, 4739 (2023).","journal-title":"J. Clin. Med."},{"key":"6061_CR14","doi-asserted-by":"publisher","first-page":"698907","DOI":"10.3389\/fphar.2021.698907","volume":"12","author":"XF Ni","year":"2021","unstructured":"Ni, X. F., Yang, C. S., Bai, Y. M., Hu, Z. X. & Zhang, L. L. Drug-related problems of patients in primary health care institutions: a systematic review. Front. Pharmacol. 12, 698907 (2021).","journal-title":"Front. Pharmacol."},{"key":"6061_CR15","unstructured":"Ministry of Health Malaysia. Clinical management of confirmed COVID-19 case in adult and paediatric. Ministry Health Malaysia  https:\/\/covid-19.moh.gov.my\/garis-panduan\/garis-panduan-kkm\/ANNEX-2E-CLINICAL-MANAGEMENT-OF-CONFIRMED-COVID-19-31052022.pdf (2022)."},{"key":"6061_CR16","unstructured":"Pharmaceutical Care Network Europe. The PCNE classification V 9.1. Pharmaceutical Care Netw. Europe https:\/\/www.pcne.org\/upload\/files\/417_PCNE_classification_V9-1_final.pdf  (2020)."},{"key":"6061_CR17","unstructured":"Pharmaceutical Services Programme, Ministry of Health Malaysia. Garis Panduan kaunseling Ubat-Ubatan Edisi Ke-3 [Medication Counselling Guideline, 3rd Edition]. Ministry Health Malaysia  https:\/\/www.pharmacy.gov.my\/v2\/sites\/default\/files\/document-upload\/gp-kaunseling-2019-isbn-final_0.pdf (2019)."},{"key":"6061_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"6061_CR19","unstructured":"Family Health Development Division, Ministry of Health Malaysia. Guideline on home monitoring and management of confirmed COVID-19 case at COVID-19 assessment centre in primary care (Annex 2m). Ministry Health Malaysia (2022)."},{"key":"6061_CR20","first-page":"1","volume":"10","author":"SK Sharma","year":"2020","unstructured":"Sharma, S. K., Mudgal, S. K., Thakur, K. & Gaur, R. How to calculate sample size for observational and experimental nursing research studies. Natl. J. Physiol. Pharm. Pharmacol. 10, 1\u20138 (2020).","journal-title":"Natl. J. Physiol. Pharm. Pharmacol."},{"key":"6061_CR21","unstructured":"COVIDNOW. https:\/\/covidnow.moh.gov.my\/bm\/cases\/sgr\/."},{"key":"6061_CR22","first-page":"602","volume":"78","author":"CL Sim","year":"2023","unstructured":"Sim, C. L. et al. Effectiveness of nirmatrelvir\/ritonavir (Paxlovid\u00ae) in preventing hospitalisation and death among COVID-19 patients: a prospective cohort study. MJM 78, 602 (2023).","journal-title":"MJM"},{"key":"6061_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/pharmacy6040109","volume":"6","author":"XY Lim","year":"2018","unstructured":"Lim, X. Y., Yeo, Q. Q., Kng, G. L. L., Chung, W. L. & Yap, K. Z. Validation of a drug-related problem classification system for the intermediate and long-term care setting in Singapore. Pharmacy 6, 109 (2018).","journal-title":"Pharmacy"},{"key":"6061_CR24","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1093\/jac\/dkaa340","volume":"75","author":"D Hodge","year":"2020","unstructured":"Hodge, D. et al. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J. Antimicrob. Chemother. 75, 3417\u20133424 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"6061_CR25","unstructured":"BC Ministry of Health \u2013 Pharmaceutical, Laboratory and Blood Services Division. Dispensing paxlovid and monitoring adverse drug events. A guide for B.C. community pharmacists. (2020)."},{"key":"6061_CR26","doi-asserted-by":"publisher","first-page":"e2242140","DOI":"10.1001\/jamanetworkopen.2022.42140","volume":"5","author":"N Hoertel","year":"2022","unstructured":"Hoertel, N., Boulware, D. R., S\u00e1nchez-Rico, M., Burgun, A. & Limosin, F. Prevalence of contraindications to nirmatrelvir-ritonavir among hospitalized patients with COVID-19 at risk for progression to severe disease. JAMA Netw. Open. 5, e2242140\u2013e2242140 (2022).","journal-title":"JAMA Netw. Open."},{"key":"6061_CR27","doi-asserted-by":"publisher","first-page":"ofac389","DOI":"10.1093\/ofid\/ofac389","volume":"9","author":"S Lim","year":"2022","unstructured":"Lim, S., Tignanelli, C. J., Hoertel, N., Boulware, D. R. & Usher, M. G. Prevalence of medical contraindications to nirmatrelvir\/ritonavir in a cohort of hospitalized and nonhospitalized patients with COVID-19. Open. Forum Infect. Dis. 9, ofac389 (2022).","journal-title":"Open. Forum Infect. Dis."},{"key":"6061_CR28","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2215\/CJN.05270522","volume":"17","author":"S Hiremath","year":"2022","unstructured":"Hiremath, S. et al. Prescribing nirmatrelvir\/ritonavir for COVID-19 in advanced CKD. Clin. J. Am. Soc. Nephrol. 17, 1247\u20131250 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"6061_CR29","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/infdis\/jiad324","volume":"228","author":"D Paraskevis","year":"2023","unstructured":"Paraskevis, D. et al. Real-world effectiveness of molnupiravir and nirmatrelvir\/ritonavir as treatments for COVID-19 in patients at high risk. J. Infect. Dis. 228, 1667\u20131674 (2023).","journal-title":"J. Infect. Dis."},{"key":"6061_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41598-020-80560-2","volume":"11","author":"N Garin","year":"2021","unstructured":"Garin, N. et al. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci. Rep. 11, 883 (2021).","journal-title":"Sci. Rep."},{"key":"6061_CR31","doi-asserted-by":"publisher","first-page":"205031212198962","DOI":"10.1177\/2050312121989625","volume":"9","author":"F Bekele","year":"2021","unstructured":"Bekele, F., Fekadu, G., Bekele, K., Dugassa, D. & Sori, J. Drug-related problems among patients with infectious disease admitted to medical wards of Wollega university referral hospital: prospective observational study. SAGE Open. Med. 9, 2050312121989625 (2021).","journal-title":"SAGE Open. Med."},{"key":"6061_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40780-024-00376-4","volume":"10","author":"T Tomida","year":"2024","unstructured":"Tomida, T. et al. Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir\/ritonavir: a retrospective observational study. J. Pharm. Health Care Sci. 10, 54 (2024).","journal-title":"J. Pharm. Health Care Sci."},{"key":"6061_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40262-023-01339-y","volume":"63","author":"J Gerhart","year":"2024","unstructured":"Gerhart, J. et al. A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir\/ritonavir. Clin. Pharmacokinet. 63, 27\u201342 (2024).","journal-title":"Clin. Pharmacokinet."},{"key":"6061_CR34","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.2646","volume":"112","author":"C Marzolini","year":"2022","unstructured":"Marzolini, C. et al. Recommendations for the management of drug\u2013drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications. Clin. Pharmacol. Ther. 112, 1191\u20131200 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"6061_CR35","doi-asserted-by":"crossref","unstructured":"Patel, E., Pevnick, J. M. & Kennelty, K. A. Pharmacists and medication reconciliation: a review of recent literature. Integr Pharm. Res. Pract 39\u201345 (2019).","DOI":"10.2147\/IPRP.S169727"},{"key":"6061_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40267-022-00971-1","volume":"39","author":"HA Blair","year":"2023","unstructured":"Blair, H. A. Nirmatrelvir plus Ritonavir in COVID-19: a profile of its use. Drugs Ther. Perspect. 39, 41\u201347 (2023).","journal-title":"Drugs Therapy Perspect."},{"key":"6061_CR37","doi-asserted-by":"publisher","first-page":"e0316573","DOI":"10.1371\/journal.pone.0316573","volume":"19","author":"J Sun","year":"2024","unstructured":"Sun, J., Deng, X., Huang, J., He, G. & Huang, S. Data mining of adverse drug event signals with nirmatrelvir\/ritonavir from FAERS. PLoS One. 19, e0316573 (2024).","journal-title":"PLoS One"},{"key":"6061_CR38","unstructured":"National Pharmaceutical Regulatory Agency, Nirmatrelvir & Ritonavir (PAXLOVID): Risk of anaphylaxis and hypersensitivity reactions. National Pharmaceutical Regulatory Agency https:\/\/www.npra.gov.my\/index.php\/en\/health-professionals\/recent-updates\/435-english\/safety-alerts-main\/safety-alerts-2022\/1527403-nirmatrelvir-ritonavir-paxlovidtm-risk-of-anaphylaxis-and-hypersensitivity.html (2022)."},{"key":"6061_CR39","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.sapharm.2021.07.002","volume":"17","author":"WY Yong","year":"2021","unstructured":"Yong, W. Y., Chang, C. T., Chew, C. C. & Khoo, T. E. Interactive virtual medication counselling in outpatient pharmacy: an accessible and safe patient counselling method during the COVID-19 pandemic. Res. Social Adm. Pharm. 17, 1860 (2021).","journal-title":"Res. Social Adm. Pharm."},{"key":"6061_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40545-023-00579-4","volume":"16","author":"CB Ng","year":"2023","unstructured":"Ng, C. B. et al. Experience and attitudes of pharmacists towards challenges and adaptive measures to new norm in ward pharmacy practice during the COVID-19 pandemic. J. Pharm. Policy Pract. 16, 85 (2023).","journal-title":"J. Pharm. Policy Pract."},{"key":"6061_CR41","unstructured":"Pharmaceutical Services Programme, Ministry of Health Malaysia. Garis Panduan Pelaksanaan kaunseling Ubat-ubatan Secara maya\/virtual [Virtual Medication Counseling Guideline]. Ministry Health Malaysia https:\/\/pharmacy.moh.gov.my\/en\/documents\/garis-panduan-pelaksanaan-kaunseling-ubat-ubatan-secara-maya-virtual.html (2021)."},{"key":"6061_CR42","doi-asserted-by":"crossref","unstructured":"Jhala, M. & Menon, R. Examining the impact of an asynchronous communication platform versus existing communication methods: an observational study. BMJ Innov. 7, (2021).","DOI":"10.7861\/fhj.7.1.s40"},{"issue":"MDPI","key":"6061_CR43","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/healthcare12050523","volume":"12","author":"C Marion","year":"2024","unstructured":"Marion, C. et al. Family involvement training for staff and family caregivers: case report on program design and mixed methods evaluation. Healthcare 12(MDPI), 523 (2024).","journal-title":"Healthcare"},{"key":"6061_CR44","doi-asserted-by":"crossref","unstructured":"Hashim, J. H., Adman, M. A., Hashim, Z., Mohd Radi, M. F. & Kwan, S. C. COVID-19 epidemic in malaysia: epidemic progression, challenges, and response. Front Public. Health 9, (2021).","DOI":"10.3389\/fpubh.2021.560592"},{"key":"6061_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.24191\/jchs.v4i1.7278","volume":"4","author":"AS Ramli","year":"2019","unstructured":"Ramli, A. S. et al. The primary health care performance initiative (PHCPI): issues and challenges for Malaysia as a trailblazer country. J. Clin. Health Sci. 4, 4\u201321 (2019).","journal-title":"J. Clin. Health Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06061-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:14:01Z","timestamp":1759238041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06061-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6061"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06061-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33852"}}